[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100463907":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":32,"locations":42,"responsibleParty":59,"collaborators":36,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":36,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":36,"enrollmentInfo":72,"targetDuration":36,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":36,"overallStatus":45,"whyStopped":36,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Spital Limmattal Schlieren","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Solution","EXPERIMENTAL","Esomeprazol MUT Sandoz® 40mg as a single dose will be dissolved in 10ml tap water to create a solution and then applied per oral",[13],"Diagnostic Test: upper endoscopy",{"label":15,"type":16,"description":17,"interventionNames":18},"Tablet","ACTIVE_COMPARATOR","Esomeprazo MUT Sandozl® 40mg tablet as a single dose will be given orally",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DIAGNOSTIC_TEST","upper endoscopy","A wireless BRAVO™ - pH monitoring device is placed and the participant is discharged with ongoing pH monitoring. The next day, the participant is randomized to either receive Esomeprazol MUT Sandoz® tablet 40mg or Esomeprazol MUT Sandoz® 40mg in solution. Serum concentration of Esomeprazol is measured at 0, 60 and 120 minutes and the patient is discharged after. After 48 hours of pH monitoring, the patient returns the BRAVO™ - recorder, adverse events are assessed and the study is terminated.",[9,15],[26],"blood sample",[28],{"name":29,"affiliation":30,"role":31},"Urs Zingg, Prof.","Limmattal Hospital","PRINCIPAL_INVESTIGATOR",[33,38],{"name":29,"role":34,"phone":35,"phoneExt":36,"email":37},"CONTACT","+41 44 733 21 26",null,"Urs.Zingg@spital-limmattal.ch",{"name":39,"role":34,"phone":40,"phoneExt":36,"email":41},"Patrizia Heeb","+41 44 736 85 76","patrizia.heeb@spital-limmattal.ch",[43],{"facility":44,"status":45,"city":46,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Spital Limmattal","RECRUITING","Schlieren","8952","Switzerland","CH",{"type":51,"coordinates":52},"Point",[53,54],8.44763,47.39668,{"lat":54,"lon":53},[57],{"name":39,"role":34,"phone":36,"phoneExt":36,"email":58},"patrizia.heeb@gmail.com",{"type":60,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":36,"oldOrganization":36},"SPONSOR_INVESTIGATOR","Prof Urs Zingg","Prof. Dr.","100463907","phase-4-the-bioavailability-and-effect-on-pouch-ph-of-esomeprazole-after-gastric-bypass-100463907",false,"NCT05320796","The Bioavailability and Effect on Pouch pH of Esomeprazole After Gastric Bypass","The Bioavailability and Effect on Pouch pH of Esomeprazole as Tablets or in Solution After Laparoscopic Proximal RYGB for Morbid Obesity - an Investigator Blinded Pilot Study","Inclusion Criteria:\n\n* Proximal Roux-en-Y gastric bypass with linear stapled anastomosis 12 months prior to the study investigation\n* Routine administration of proton pump inhibitors for 6 months postoperatively\n* No intake of proton pump inhibitors at least 4 weeks prior to study investigation\n* No marginal ulcers in upper endoscopy prior to placement of wireless BRAVO™ pH monitoring capsule\n* No symptoms related to gastro-esophageal reflux or marginal ulcers (i.e. epigastric pain, retrosternal burning, regurgitation)\n* Informed consent as documented by signature\n\nExclusion Criteria:\n\n* Known intolerance or allergy for Esomeprazol\n* Contraindication for upper endoscopy\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant\n* Women who are pregnant or breast feeding Major hepatic dysfunction","ALL","18 Years",{"count":73,"type":74},50,"ESTIMATED","INTERVENTIONAL",[77],"PHASE4","The objective of this study is to investigate the effect of Esomeprazol administered in tablets (Esomeprazol MUT Sandoz® 40mg) or in solution (Esomeprazol MUT Sandoz® 40mg in 10ml tap water) on acid production in the gastric pouch by measuring the intragastric pH and the serum concentration of esomeprazole.",[80,81,82],"Obesity","Gastric Reflux","Ulcer, Gastric","2026-06-08",{"date":85,"type":86},"2026-06-09","ACTUAL",{"date":88,"type":86},"2023-11-01",{"date":90,"type":74},"2027-12-31",{"name":61,"class":6},1]